Sponsored Events (Non-Accredited)

2025 Corporate Therapeutic Symposia Schedule

Non-Accredited 

Lunch will be served during all Corporate Therapeutic Symposia; No other lunches are available at the International Congress. 
 

 Sunday, October 5, 12:15 - 13:15 

Supernus Pharmaceuticals
Scientific Foundations and Clinical Applications: Where ONAPGO, Continuous Apomorphine Infusion, Fits in Today's Standard of Care

Join Supernus Pharmaceuticals for an interactive discussion on redefining the standard of care. 

Speakers: Robert Hauser, Stuart Isaacson, Daniel Kremens, Maria Cristina Ospina
 

AbbVie
Sharing Experiences and Learnings Around Continuous Levodopa-Based Therapy for Advanced PD Patients: Why, What, How, and Who?

This symposium highlights the role of continuous subcutaneous levodopa-based infusion in managing advanced Parkinson’s disease, with insights on patient selection, real-world outcomes, and addressing unmet needs. 

• Advanced PD Comes With a 24 Hour Burden - Irene Malaty
• Addressing Unmet Medical Needs With Continuous Subcutaneous Levodopa-Based Infusion in Patients Uncontrolled on Oral Medications - Jason Aldred 
• Learning from the Real-World Experience: Successful Management of Continuous Subcutaneous Levodopa-Based Infusio - Rajesh Pahwa & Bruno Bergmans
   

Merz Therapeutics GmbH
Overcoming Gastrointestinal Barriers: A Treatment Option in Acute OFF Episode Management in PD

This symposium will explore the use of inhaled levodopa as an on-demand therapy that bypasses gastrointestinal barriers to manage acute OFF episodes in Parkinson’s disease.

Speakers: Drew Falconer, Laren Becker

 

 Monday, October 6, 12:15 - 13:15 

Acadia Pharmaceuticals Inc.*
Taking Action in Parkinson's Disease Psychosis Defining the Importance of Timely Treatment

Join us for an engaging, 60-minute, live expert discussion on Parkinson's disease psychosis (PDP), where we’ll explore the journey from symptom burden to effective diagnosis and treatment plans. This event will feature leading neurologists and mental health professionals who will share their insights on the often-overlooked symptoms of psychosis, including hallucinations and delusions, and how they impact patients and their families.

Attendees will have the opportunity to interact directly with our panel of experts, asking questions and sharing experiences in real-time. We’ll delve into the latest diagnostic criteria and innovative treatment strategies designed to enhance the quality of life for those affected by this condition. Don’t miss this chance to gain valuable knowledge and connect with others in the community.

*Live and enduring accreditation by Medscape, LLC.
 
Speakers: Jennifer Hui, William Ondo
 

Amneal Pharmaceuticals
Innovation and Outcomes: A Case-Based Discussion About CREXONT® (carbidopa and levodopa) Extended-Release Capsules

Join Amneal for a Corporate Therapeutic Symposia, where Drs Espay, Farmer, and Thakkar will explore key topics, including the clinical efficacy and safety profile of CREXONT, guidance on initiating dosing, and insights from their clinical experience. This session aims to deepen our understanding of this innovative treatment option.
 
Speakers: Alberto Espay, Jill Farmer, Sandeep Thakkar
 

Biogen
Exploring the Clinical Efficacy and Safety Data of SKYCLARYS (omaveloxolone)

Join us at the Biogen symposium where Dr. Zesiewicz will discuss SKYCLARYS (omaveloxolone) data as well as patient cases from clinical practice.

Speaker: Theresa Zesiewicz

 

 Tuesday, October 7, 12:15 - 13:15 

Amneal Pharmaceuticals Inc.
The Benefits of COMT Inhibition for Patients with Parkinson's Disease: Maximizing Your Treatment Strategy with ONGENTYS® (opicapone) Capsules

Drs. Sagari Betté and Stuart Isaacson will explore the role of COMT in levodopa metabolism and discuss the efficacy, safety, and key treatment considerations of ONGENTYS for managing “Off” time.
 
Speakers: Stuart Isaacson, Sagari Betté
 

AskBio Inc.
Patient-Focused Innovation in Parkinson's Care: GDNF Gene Therapy and the REGENERATE-PD Study

Gene therapy represents a promising strategy in the treatment of neurodegenerative diseases. This session explores its emerging role in Parkinson’s disease (PD), with a focus on the delivery of GDNF (glial cell line-derived neurotrophic factor) to targeted brain regions. Experts will examine the limitations of current symptomatic treatments, potential intervention to address the underlying disease pathology, and the science behind AskBio’s investigational REGENERATE-PD program. Attendees will gain foundational insight into gene therapy’s mechanism of action and the rationale behind GDNF as a disease-modifying candidate. The program is designed to enhance clinicians’ understanding of gene therapy’s therapeutic potential in Parkinson’s disease, integrating both scientific insights and patient experiences.
 
Speakers: Pinky Agarwal, Khashayar Dashtipour, Rajesh Pahwa
 

 

 Wednesday, October 8, 11:45 - 12:45 

H Lundbeck A/S
Exploring MSA: Bridging Clinical Insight, Experiences of People Living with MSA, and the Path Toward Targeted Treatment

Join expert faculty in MSA where they will:

• Discuss the early symptoms and diease progression of MSA and the importance of timely and accurate diagnosis
• Review the current clinical diagnostic criteria and explore the potential role of biomarkers in facilitating early detection
• Hear real-world insights from a person living with MSA, covering their journey to diagnosis, daily impact and unmet treatment needs
• Discuss current approaches to disease management and explore emerging potential treatment options

There will be an opportunity for discussion and to ask questions to the experts.  

Speakers: Horacio Kaufmann, Wasilios Meissner, Wolfgang Singer, Günter Höglinger

2025 Innovation Showcase Schedule 
Non-Accredited 

 Sunday, October 5, 15:00 - 15:30 

AbbVie
Targets for Next-Generation PD Therapies: Can We Learn From History to Find a Different Approach?

This session will review the roles of D1-like and D2-like dopamine receptors in brain function and Parkinson’s disease therapy. Faculty will discuss lessons from past dopamine agonists and explore how selective D1-like receptor therapies may address unmet needs in symptomatic treatment.

Speakers: Hubert Fernandez & Daniel Claasen

 

 Tuesday, October 7, 09:30 - 10:00 

Medtronic
Riding the Next Wave in Parkinson’s Care: Adaptive DBS in Action - A Hawaiian Perspective

Join us for a live session with Dr. Fay Gao, Neurologist at the Parkinson’s and Movement Center, Queens Neuroscience Institute, The Queen’s Health System, Honolulu.

Dr. Gao will share her early experiences with BrainSense™ and the capabilities of adaptive Deep Brain Stimulation (DBS). She will be joined by one of her patients for a discussion and live demonstration, offering insights into the features and real-world impact of the technology.

Don’t miss this opportunity to see the system in action and hear firsthand how it’s making a difference.

Speaker: Fay Gao

 

 Wednesday, October 8, 09:30 - 10:00 

Boston Scientific
DBS Programming with Illumina 3D™ Technology: Designed for Faster Programming, Stable Therapy, and Better Outcomes*

Gain insights into the evolving role of Image Guided Programming (IGP) in Deep Brain Stimulation (DBS) therapy with the Boston Scientific DBS System, featuring the Vercise™ Cartesia™ X 16-contact directional lead and Illumina 3D™ technology.

This session presents real-world case studies and clinical experiences that demonstrate how IGP supports precise, patient-specific stimulation planning. By visualizing lead placement within individual anatomy, clinicians can tailor therapy more efficiently—optimizing outcomes and minimizing side effects.

Speakers: Mahsa Malekmohammadi, Danielle Englert, & Michele Tagliati

*Lange F, et al. Reduced Programming Time and Strong Symptom Control Even in Chronic Course Through Imaging-Based DBS Programming. Front Neurol. 2021 Nov 8;12:785529. N=10. Torres V, et al. Image-guided programming deep brain stimulation improves clinical outcomes in patients with Parkinson’s disease. NPJ Parkinsons Dis. 2024 Jan 27;10(1):29. Aldred J, et al. (2023). Image-Guided Programming Tool for DBS Programming Reduces Initial DBS Programming Time and Allows for Sustained Settings Long-Term. MDS 2023 Poster.
All U.S. Physicians – The U.S. Physician Payment Sunshine Act requires all pharmaceutical, biologics and medical device companies to disclose annually to the U.S. government payments and transfers of value provided to U.S. physicians and teaching hospitals. This includes the value of meals and refreshments provided to U.S. physicians in connection with attending Boston Scientific educational programs.
View Boston Scientific Deep Brain System Indications, Safety, and Warnings at bostonscientific.com/dbs-indications.